{"id":1280,"date":"2026-11-09T10:31:00","date_gmt":"2026-11-09T15:31:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=1280"},"modified":"2026-11-03T21:42:52","modified_gmt":"2026-11-04T02:42:52","slug":"your-patient-support-data-starts-after-enrollment-ai-questions-start-before-it","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/your-patient-support-data-starts-after-enrollment-ai-questions-start-before-it\/","title":{"rendered":"Your Patient Support Data Starts After Enrollment. AI Questions Start Before It."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

In a KFF poll fielded February 24 to March 2, 2026, 32% of U.S. adults said they had used an AI chatbot for health information in the past year. [1] Of those users, 41% said they used it to look up information before deciding whether to see a provider. [1] A patient support program (PSP) cannot see any of that activity. Its first data point is the enrollment form, and by that point the patient has already asked questions, received answers, and formed expectations about cost, eligibility, and what the first month of therapy will look like.<\/p>\n\n\n\n

This article maps the gap between the first AI question and the first PSP record. It uses public data from KFF, OpenAI, IQVIA, Guidehouse, the Oxford Internet Institute, the HHS Office of Inspector General (OIG), the European Medicines Agency (EMA), and the Code of Federal Regulations. It does not report original testing of AI platforms. It does give a reproducible method for running that testing, and it labels every calculated figure as analysis.<\/p>\n\n\n\n

The Short Answer: What Is the Pre-Enrollment Data Gap?<\/strong><\/h2>\n\n\n\n

The pre-enrollment data gap is the period between a patient’s first AI-generated answer about a drug and the first record in a hub, specialty pharmacy, or copay program. During that period, the patient may rely on an answer that no one at the manufacturer has seen, tested, or corrected. This definition is an analytical framing used in this article. It is not an established industry term.<\/p>\n\n\n\n

The Five Findings That Matter<\/strong><\/h3>\n\n\n\n
    \n
  1. 32% of U.S. adults used AI chatbots for health information in the past year, equal to the share who used social media for the same purpose (KFF, March 2026). [1]<\/li>\n\n\n\n
  2. OpenAI reported that more than 40 million people ask ChatGPT health questions each day, and that users send more than 1.5 million to nearly 2 million health-insurance messages each week. [2]<\/li>\n\n\n\n
  3. A BMJ Quality & Safety study of 500 Bing Copilot answers on 50 common drugs found that 26% of the 484 evaluated answers did not match reference data. [3][4]<\/li>\n\n\n\n
  4. A randomized Oxford trial with nearly 1,300 participants found that people using large language models (LLMs) did not make better health decisions than a control group. [5]<\/li>\n\n\n\n
  5. IQVIA reported that commercial new-to-brand abandonment rose 27% from 2016 to 2020, driven mainly by out-of-pocket costs above $50 and most sharply above $125. [6]<\/li>\n<\/ol>\n\n\n\n

    Together, these findings point to an operational problem. Patients ask AI systems about cost and access before they reach the services designed to answer those questions. The evidence on AI accuracy is mixed and mostly not specific to program terms. That is the second gap: no public study we found tests whether AI answers about a given copay program, eligibility rule, or hub phone number are current.<\/p>\n\n\n\n

    What Does a Patient Support Program Actually See?<\/strong><\/h2>\n\n\n\n

    A PSP sees what patients and prescribers send it. Everything before that point is invisible to program reporting. This section defines the data boundary.<\/p>\n\n\n\n

    What Data Fields Does a Hub Capture?<\/strong><\/h3>\n\n\n\n

    A typical hub records enrollment, benefits verification, prior authorization status, copay-card activation, specialty pharmacy handoff, and refill timing. The exact fields vary by manufacturer and vendor. The Guidehouse 2025 Patient Services Trends Survey, which polled 35 PSP and market access executives in the first quarter of 2025, found that nearly 60% of respondents said at least half of the patients in their programs use hub services. [10] That is a statement about patients already in the program. It says nothing about patients who never entered.<\/p>\n\n\n\n

    When Does the PSP Record Begin?<\/strong><\/h3>\n\n\n\n

    The record begins at the first transaction, which is usually a prescriber-submitted enrollment form, a patient-initiated sign-up, or a pharmacy-triggered referral. Each of these needs a patient who already knows the program exists.<\/p>\n\n\n\n

    The Enrollment Form as the First Data Point<\/strong><\/h4>\n\n\n\n

    An enrollment form holds demographics, insurance details, prescriber information, and consent. It does not hold the patient’s earlier questions, the sources the patient read, or the reason the patient chose to enroll.<\/p>\n\n\n\n

    What a Missed Patient Looks Like in Hub Reporting<\/strong><\/h4>\n\n\n\n

    A patient who abandons before enrollment does not appear as a failed case. The patient does not appear at all. Hub dashboards count the denominator of enrolled patients, so pre-enrollment loss lowers real-world uptake without changing any reported rate. This is an inference from how enrollment-based reporting works, not a measured statistic.<\/p>\n\n\n\n

    How Many People Ask AI Health Questions Before They See a Clinician?<\/strong><\/h2>\n\n\n\n

    Two public sources give scale: a KFF poll of U.S. adults and a usage report from OpenAI. They measure different things, so this article does not combine them into one number.<\/p>\n\n\n\n

    What Does the KFF 2026 Poll Show?<\/strong><\/h3>\n\n\n\n

    KFF surveyed 1,343 U.S. adults online and by telephone, in English and Spanish, with a margin of sampling error of plus or minus 3 percentage points. [1] The poll found the following:<\/p>\n\n\n\n

      \n
    • 32% of adults used AI chatbots for health information in the past year. [1]<\/li>\n\n\n\n
    • 29% sought information about physical health, and 16% about mental health. [1]<\/li>\n\n\n\n
    • 65% of users cited quick or immediate information, 41% wanted to look up information before deciding whether to see a provider, and 36% preferred to look up information privately. [1]<\/li>\n\n\n\n
    • 19% said cost kept them from seeing a professional. [1]<\/li>\n\n\n\n
    • 41% of AI health users uploaded personal medical information such as test results or doctors’ notes, equal to 13% of all adults. [1]<\/li>\n<\/ul>\n\n\n\n
      \n

      “32% of U.S. adults said they used AI chatbots in the past year for health information.” (KFF Health Misinformation Tracking Poll, March 25, 2026) [1]<\/p>\n<\/blockquote>\n\n\n\n

      KFF does not report how many of these users asked about a specific prescription drug or a manufacturer program. The poll shows demand for pre-visit information. It does not show how often that demand includes program or cost questions.<\/p>\n\n\n\n

      What Does OpenAI Report About Health Questions on ChatGPT?<\/strong><\/h3>\n\n\n\n

      OpenAI’s January 2026 report, “AI as a Healthcare Ally,” states that more than 5% of all ChatGPT messages globally are about healthcare. [2] It also states that of more than 800 million regular users, one in four submits a healthcare prompt every week, and that more than 40 million people ask healthcare questions every day. [2] The report says seven in 10 healthcare conversations happen outside normal clinic hours, defined as outside 8 a.m. to 5 p.m. local time. [2]<\/p>\n\n\n\n

      For U.S. users, OpenAI reported that ChatGPT users send more than 1.5 million to nearly 2 million messages about health insurance each week. [2] The listed topics include comparing plans, understanding prices, handling claims and billing, eligibility and enrollment, and coverage and cost-sharing details. [2]<\/p>\n\n\n\n

      What the OpenAI Figures Do Not Show<\/strong><\/h4>\n\n\n\n

      The report does not give usage counts for medication questions or for cost questions about specific drugs. [2] It is a company report, not an independent audit. Readers should treat the figures as the platform operator’s own disclosure.<\/p>\n\n\n\n

      Annualized Insurance Message Volume (Calculated)<\/strong><\/h4>\n\n\n\n

      Analysis: at 1.5 million messages per week, the annual total is 78 million (1.5 million x 52). At 2 million per week, it is 104 million. This calculation assumes the weekly rate stays constant for a year. OpenAI did not report an annual figure. [2]<\/p>\n\n\n\n

      What Questions Do Patients Ask Before Enrollment?<\/strong><\/h2>\n\n\n\n

      No public dataset lists real pre-enrollment questions about specific branded drugs. The classification below is an original framework built from the topics OpenAI and KFF report and from the services a PSP typically provides. It is a hypothesis for testing, not an observed distribution.<\/p>\n\n\n\n

      A Five-Type Taxonomy of Pre-Enrollment Questions<\/strong><\/h3>\n\n\n\n

      The taxonomy sorts questions by the program function that would answer them.<\/p>\n\n\n\n

      Type 1: Eligibility Questions<\/strong><\/h4>\n\n\n\n

      Example: “Can I use a copay card if I have Medicare?” The correct answer depends on program terms and federal rules, and the terms change.<\/p>\n\n\n\n

      Type 2: Cost and Coverage Questions<\/strong><\/h4>\n\n\n\n

      Example: “How much will this drug cost me with my plan?” The answer depends on formulary tier, deductible status, and plan design. A general-purpose model has none of those inputs.<\/p>\n\n\n\n

      Type 3: Access-Pathway Questions<\/strong><\/h4>\n\n\n\n

      Example: “Where do I get this drug if my pharmacy does not stock it?” The answer depends on whether the drug is routed through a limited-distribution specialty pharmacy.<\/p>\n\n\n\n

      Type 4: Start-Up and Administration Questions<\/strong><\/h4>\n\n\n\n

      Example: “What do I do on the first day?” The answer depends on the current prescribing information and on any nurse-training offer.<\/p>\n\n\n\n

      Type 5: Safety and Expectation Questions<\/strong><\/h4>\n\n\n\n

      Example: “Is it normal to feel nauseated in week one?” The answer depends on the label’s adverse reactions section and on clinical judgment. This type connects to pharmacovigilance, covered below.<\/p>\n\n\n\n

      Reference Table: Question Type, Owning Function, and Risk if the Answer Is Wrong<\/strong><\/h3>\n\n\n\n
      Question type<\/th>Authoritative source<\/th>Owning function<\/th>Risk if an AI answer is stale or wrong (analysis)<\/th><\/tr><\/thead>
      1. Eligibility<\/td>Program terms and conditions; OIG guidance [7]<\/td>Patient support, Legal<\/td>Patient applies, is rejected, and may abandon; or a federal-program patient uses a prohibited coupon<\/td><\/tr>
      2. Cost and coverage<\/td>Plan documents; CMS Part D rules [12]<\/td>Market access, Patient support<\/td>Patient expects a lower or higher price than will apply at the counter [6]<\/td><\/tr>
      3. Access pathway<\/td>Manufacturer distribution notice<\/td>Trade, Patient support<\/td>Patient looks for the drug in the wrong channel<\/td><\/tr>
      4. Start-up and administration<\/td>FDA prescribing information<\/td>Medical Information, Regulatory<\/td>Dosing or preparation error<\/td><\/tr>
      5. Safety and expectation<\/td>FDA prescribing information<\/td>Medical Information, Pharmacovigilance<\/td>Patient stops therapy without advice or misses a warning sign<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      The risk column is analysis. The sources column identifies the document that would settle a dispute about the answer.<\/p>\n\n\n\n

      What Does the Evidence Say About AI Accuracy on Drug Information?<\/strong><\/h2>\n\n\n\n

      The evidence is limited and mostly pre-dates the current generation of models. Two studies are directly relevant to a patient asking about a drug.<\/p>\n\n\n\n

      What Did the BMJ Quality & Safety Chatbot Study Find?<\/strong><\/h3>\n\n\n\n

      Andrikyan and colleagues at Friedrich-Alexander-Universitat Erlangen-Nurnberg published a cross-sectional study in BMJ Quality & Safety on October 1, 2024. [3] The team asked Bing Copilot 10 questions about each of the 50 most frequently prescribed drugs in the U.S. in 2020, which produced 500 answers. [4] The reported results, as summarized by News-Medical, were:<\/p>\n\n\n\n

        \n
      • Average completeness was 77%, with the lowest-scoring question (what to consider when taking the drug) at 23%. [4]<\/li>\n\n\n\n
      • 126 of 484 evaluated answers (26%) did not match reference data, and 16 (just over 3%) were fully inconsistent. [4]<\/li>\n\n\n\n
      • The average Flesch Reading Ease score was just over 37, which corresponds to degree-level reading ability. [4]<\/li>\n<\/ul>\n\n\n\n

        The harm ratings came from a subset of 20 answers that the authors selected for low accuracy, low completeness, or potential safety risk. In that subset, seven experts rated 42% as likely to lead to moderate or mild harm and 22% as likely to lead to death or severe harm. [4] These percentages do not describe all 500 answers. The study also did not use real patient experiences. [4]<\/p>\n\n\n\n

        What the BMJ Study Does Not Tell You<\/strong><\/h4>\n\n\n\n

        It tested one product (Bing Copilot) in 2024. It did not test manufacturer program terms. A reader cannot apply its accuracy rate to current ChatGPT, Claude, Gemini, or Perplexity answers.<\/p>\n\n\n\n

        What Did the Oxford Nature Medicine Trial Find?<\/strong><\/h3>\n\n\n\n

        A team from the Oxford Internet Institute and the Nuffield Department of Primary Care Health Sciences ran a randomized trial with nearly 1,300 online participants. [5] One group used an LLM to decide on a condition and a next step. A control group used search engines or its own judgment. [5] LLM users did not make better decisions than the control group. [5]<\/p>\n\n\n\n

        The researchers named three problems: users often did not know what information to provide, small wording changes produced very different answers, and responses mixed good and bad advice that was hard to separate. [5] Dr. Rebecca Payne, the lead medical practitioner on the study, said: “Despite all the hype, AI just isn’t ready to take on the role of the physician.” [5]<\/p>\n\n\n\n

        Why Program Terms Are a Different Test<\/strong><\/h4>\n\n\n\n

        Both studies tested clinical content. A copay program’s age limits, income rules, and exclusions are not in the prescribing information. They sit in program terms that change by manufacturer and by year. This article found no published study of AI accuracy on those terms. That absence is itself a finding, and it is the reason the method section below exists.<\/p>\n\n\n\n

        Where Do Cost and Coverage Questions Meet Changing Rules?<\/strong><\/h2>\n\n\n\n

        Cost questions are the most time-sensitive category in the taxonomy. Three rule sets that changed or were announced recently affect the answer a patient should receive.<\/p>\n\n\n\n

        Can a Medicare Patient Use a Manufacturer Copay Card?<\/strong><\/h3>\n\n\n\n

        No, manufacturers generally structure copay programs to exclude patients whose drugs are paid by federal health care programs. The OIG issued a Special Advisory Bulletin on September 19, 2014, on manufacturer copayment coupons and Medicare Part D. [7] It stated that manufacturers risk Anti-Kickback Statute sanctions if coupons induce purchases of drugs paid for by federal programs, and that a failure to take appropriate steps to prevent this may be treated as evidence of intent to induce. [7]<\/p>\n\n\n\n

        The OIG’s companion report found that two common safeguards, notices and pharmacy claims edits, may be inadequate because notices are often inconspicuous and claims edits are not audited. [7] This is why an AI answer that says “use the manufacturer’s coupon” without a Medicare caveat is a Type 1 error with compliance implications. That sentence is analysis, not an observed AI response.<\/p>\n\n\n\n

        What Is the 2026 Medicare Part D Out-of-Pocket Cap?<\/strong><\/h3>\n\n\n\n

        The 2026 Part D out-of-pocket cap is $2,100, up from $2,000 in 2025. [12] Payments toward deductibles, copays, and coinsurance for covered drugs count toward it. After a patient reaches the cap, the patient pays nothing out of pocket for covered prescriptions for the rest of the year. [12] The Medicare Prescription Payment Plan, introduced in 2025, lets Part D patients spread out-of-pocket costs across monthly payments, and enrollment is optional. [12]<\/p>\n\n\n\n

        Analysis: the cap equals $175 per month if spread evenly over 12 months ($2,100 divided by 12). An AI answer that quotes the 2025 figure is out of date by $100, or 5%. These are calculated figures. The cap has no single monthly amount in the rule itself.<\/p>\n\n\n\n

        How Did TrumpRx Change the Cash-Price Question?<\/strong><\/h3>\n\n\n\n

        TrumpRx.gov launched on February 5, 2026, with more than 40 drugs from five manufacturers that had Most Favored Nation pricing deals: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. [11] It is a direct-to-consumer channel for cash-paying patients. For Zepbound, ordering a vial redirects the user to LillyDirect. For Wegovy pens, the user receives a pharmacy coupon. [11] The source article did not say whether cash purchases count toward insurance deductibles. [11]<\/p>\n\n\n\n

        Cash-Price Reductions in the Launch Coverage (Calculated)<\/strong><\/h4>\n\n\n\n
        Product<\/th>List price per month [11]<\/th>TrumpRx price per month [11]<\/th>Reduction (analysis)<\/th><\/tr><\/thead>
        Wegovy injectable<\/td>$1,349<\/td>Average $350<\/td>74%<\/td><\/tr>
        Wegovy oral<\/td>$1,349<\/td>$149 (varies by dose)<\/td>89%<\/td><\/tr>
        Zepbound<\/td>$1,088<\/td>Average $346; as low as $299<\/td>68% at average; 73% at lowest<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        The reduction column divides the difference by the list price and rounds to the nearest percent. Prices were as reported on the launch date. They may have changed, which is the point: an AI model with a training cutoff or a cached page may quote a price that no longer applies.<\/p>\n\n\n\n

        What Does Abandonment Data Say About Why the Pre-Enrollment Stage Matters?<\/strong><\/h2>\n\n\n\n

        Abandonment data tie cost expectations to behavior. The data below come from IQVIA and Guidehouse, and both have methodology limits.<\/p>\n\n\n\n

        How Does Out-of-Pocket Cost Affect Abandonment?<\/strong><\/h3>\n\n\n\n

        IQVIA’s November 30, 2021 analysis covered commercial new-to-brand patients across 15 major therapeutic categories from 2016 to 2020. [6] It reported the following:<\/p>\n\n\n\n

          \n
        • Overall commercial abandonment rose 27% over the period, driven mainly by patients asked to pay more than $50, and most sharply by those asked to pay more than $125. [6]<\/li>\n\n\n\n
        • Medicare Part D patients asked to pay more than $75 abandoned therapy roughly 25% of the time. [6]<\/li>\n\n\n\n
        • In commercial immunology from 2018 to 2020, lower out-of-pocket costs through copay cards improved effective adherence by 87%. [6]<\/li>\n\n\n\n
        • Patients who routinely paid more than $75 monthly had about 40% fewer days of therapy per year than those paying under $20. [6]<\/li>\n<\/ul>\n\n\n\n

          The blog post did not give sample sizes or a full methodology, and it did not publish band-level percentages in text. [6] The data are four to six years old. They show a direction, not a current rate.<\/p>\n\n\n\n

          What Does the Guidehouse 2025 Survey Say About Program Awareness and AI?<\/strong><\/h3>\n\n\n\n

          Guidehouse surveyed 35 PSP and market access executives at pharmaceutical firms in the first quarter of 2025. [10] Among the findings:<\/p>\n\n\n\n

            \n
          • 80% of respondents named copay assistance among the most-used services. [10]<\/li>\n\n\n\n
          • 71% cited innovative technology as a must-have in a hub vendor. [10]<\/li>\n\n\n\n
          • Respondents listed automated prior authorization and billing support (60% patient-facing, 54% provider-facing) and AI-supported health assistants (43% patient-facing, 34% provider-facing) among next-generation services. [10]<\/li>\n\n\n\n
          • One executive said copay programs are underutilized because many patients still do not know about them. That is an anecdote, not a measured rate. [10]<\/li>\n<\/ul>\n\n\n\n

            With 35 respondents, the survey is a small sample of industry opinion, not a measurement of patient behavior. It shows that program owners see low awareness as a problem and are planning AI-based assistants. It does not show what third-party AI systems say about those programs.<\/p>\n\n\n\n

            What Does the Pre-Enrollment Gap Mean for Pharmacovigilance?<\/strong><\/h2>\n\n\n\n

            Safety data flow into pharmacovigilance (PV) through defined channels. Pre-enrollment AI conversations are outside those channels unless a company receives the information. This section separates what the rules say from what remains open.<\/p>\n\n\n\n

            How Do the Rules Treat Safety Information From Patient Support Programs?<\/strong><\/h3>\n\n\n\n

            In the U.S., 21 CFR 314.80(b) requires an applicant to promptly review all adverse drug experience information it obtains or otherwise receives from any source, foreign or domestic. The listed sources include commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological or surveillance studies, reports in the scientific literature, and unpublished scientific papers. [9] Section 314.80(c)(1)(i) requires a report of each serious and unexpected adverse drug experience as soon as possible and in no case later than 15 calendar days after initial receipt. [9]<\/p>\n\n\n\n

            In the EU, GVP Module VI, section VI.C.2.2.11, states that safety reports originating from patient support programmes should be considered solicited reports. [8] A marketing authorisation holder must assess causality so that only suspected adverse reactions are reported as valid individual case safety reports. [8] Under Directive 2001\/83\/EC, Article 107(3), serious suspected reactions go to EudraVigilance within 15 days and non-serious suspected reactions in the EU within 90 days. [8]<\/p>\n\n\n\n

            The EMA source is a conference presentation by an author who states that the views are personal and not adopted guidance. [8] Readers should check the current text of GVP Module VI before relying on section numbers.<\/p>\n\n\n\n

            Does an AI Conversation Outside the Company Create a PV Obligation?<\/strong><\/h3>\n\n\n\n

            Based on the text above, the trigger is information the company obtains or receives. [9] A patient’s private conversation with a general-purpose chatbot is not received by the company. Reading the rules this way, no reporting obligation arises from that conversation alone. This is an interpretation, not legal advice. PV and Legal teams should confirm it for their own product and jurisdiction.<\/p>\n\n\n\n

            The operational point is different. Type 5 questions often contain safety content. If an AI answer gets a labeled risk wrong, such as understating a warning, the patient may enter the PSP with a distorted view of the drug. The hub nurse is then the first person at the company to hear a symptom report, and that report is within the regulatory definitions above.<\/p>\n\n\n\n

            If a Company Deploys Its Own AI Assistant<\/strong><\/h4>\n\n\n\n

            A manufacturer-branded assistant that takes patient messages is a channel the company controls. Any adverse event text it captures is information the company receives. The Guidehouse survey indicates some manufacturers plan patient-facing AI assistants. [10] Those teams need an adverse-event detection and routing step before launch. This is a design recommendation derived from the rules cited above. It is not a regulatory requirement stated in those rules.<\/p>\n\n\n\n

            How Can a Team Measure What AI Says Before Enrollment?<\/strong><\/h2>\n\n\n\n

            A team can measure it by sampling AI answers to a fixed question set and scoring each answer against current authoritative documents. The protocol below is designed so another researcher can repeat it. It has not been run for this article, and no results are reported here.<\/p>\n\n\n\n

            A Reproducible Monitoring Protocol<\/strong><\/h3>\n\n\n\n

            Record the following for every run, so the analysis can be reproduced:<\/p>\n\n\n\n

              \n
            • AI platform and model name, with the version string if the platform shows one.<\/li>\n\n\n\n
            • Exact prompt text, including any system or persona text.<\/li>\n\n\n\n
            • Date and time of the run, with time zone.<\/li>\n\n\n\n
            • Whether web search was enabled and whether citations were requested.<\/li>\n\n\n\n
            • Geographic context and account state (logged in or out, memory on or off).<\/li>\n\n\n\n
            • The drug, indication, and insurance scenario in the question.<\/li>\n\n\n\n
            • The version and date of each reference document: prescribing information, program terms, and plan or CMS rule.<\/li>\n<\/ul>\n\n\n\n

              Run each question multiple times, because the Oxford study found that small wording changes produced very different answers. [5] Treat repeated identical responses as one observation and count the variants separately.<\/p>\n\n\n\n

              How Should Discrepancies Be Classified?<\/strong><\/h3>\n\n\n\n

              Use two scales. The first scale is the five question types in the taxonomy above. The second scale is the error category:<\/p>\n\n\n\n

              Error category<\/th>Definition<\/th>Example check<\/th><\/tr><\/thead>
              Outdated<\/td>Was correct at an earlier date; not correct now<\/td>Quotes the 2025 Part D cap of $2,000 instead of $2,100 [12]<\/td><\/tr>
              Contradicted<\/td>Conflicts with the current authoritative source<\/td>Says a copay card is available to Medicare patients [7]<\/td><\/tr>
              Unsupported<\/td>No authoritative source states the claim<\/td>Gives a program phone number or price with no source<\/td><\/tr>
              Missing<\/td>Omits a required caveat or warning<\/td>Omits the Medicare exclusion or a labeled warning<\/td><\/tr>
              Wrong channel<\/td>Directs the patient to a nonexistent or inappropriate path<\/td>Names a retired program or the wrong website<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

              This error taxonomy is an original framework. It is not an established industry classification. Assign severity in a separate step: no consequence, wasted effort, delayed start, financial harm, or clinical harm.<\/p>\n\n\n\n

              Example Sample Design<\/strong><\/h3>\n\n\n\n

              A design example: 20 questions, spread across the five types, run on 5 platforms, once a week for 4 weeks, produces 400 responses (20 x 5 x 4). That total is a design number, not a result. A single team should state the sample size and avoid generalizing to all AI-generated drug information.<\/p>\n\n\n\n

              How Does DrugChatter Fit Into This Method?<\/strong><\/h4>\n\n\n\n

              DrugChatter (drugchatter.com) is one tool that runs scheduled question sets across multiple AI models and compares the responses with drug-label content. A team could use it to automate the capture steps above. It does not replace the reference documents, and a human reviewer should confirm each flagged discrepancy against the primary source.<\/p>\n\n\n\n

              Limitations of This Approach<\/strong><\/h4>\n\n\n\n

              A fixed question set may not match the wording real patients use. Models change without notice, so a result is true for its run date only. Platforms personalize answers, so a logged-out test may differ from a patient’s own session. KFF reports that 41% of AI health users uploaded personal medical information, which a test account cannot replicate. [1]<\/p>\n\n\n\n

              What Does This Mean for Each Function?<\/strong><\/h2>\n\n\n\n

              The five question types map to different owners. The table above names them. The points below give a practical starting action for each.<\/p>\n\n\n\n

              What This Means for Patient Support Teams<\/strong><\/h3>\n\n\n\n

              Audit every public statement of program terms, including PDFs, old press pages, and third-party listings. A model can learn from any indexed copy. Compare enrollment-form drop-off against the question types above. If many applicants fail the same eligibility check, a stale outside answer may be one cause. That hypothesis needs the test described above.<\/p>\n\n\n\n

              What This Means for Medical Affairs and Medical Information<\/strong><\/h3>\n\n\n\n

              Medical Information teams answer unsolicited requests from clinicians and patients. They can add a short list of “questions we see most” to their intake review and compare it with the AI test set. The test set should include Type 4 and Type 5 questions that map to the prescribing information.<\/p>\n\n\n\n

              What This Means for Brand Teams<\/strong><\/h3>\n\n\n\n

              Brand teams control the web pages that AI systems may cite. A single, dated, plain-language program page is easier to cite correctly than five overlapping pages. The accuracy risk falls on the brand even when the patient never visits the brand site.<\/p>\n\n\n\n

              What This Means for Regulatory Affairs and Legal<\/strong><\/h3>\n\n\n\n

              Review the Medicare and federal-program language on every program page against the OIG bulletin. [7] Decide in advance who may correct a third-party AI error and how. Correcting a model’s output is not the same as promoting the drug, and the rules for promotional communications still apply to any statement the company writes. Counsel should set the line.<\/p>\n\n\n\n

              What Happens Next?<\/strong><\/h2>\n\n\n\n

              Three developments are documented as of November 3, 2026. OpenAI reports that health is more than 5% of ChatGPT messages worldwide. [2] Cash-pay channels such as TrumpRx now sit beside insurance-billed paths, so patients have more price routes to ask about. [11] The Part D cap rose from $2,000 to $2,100 between 2025 and 2026, so any answer built on 2025 text is already wrong on that point. [12]<\/p>\n\n\n\n

              What is not documented: a published, repeatable audit of AI answers about manufacturer program terms. Until one exists, each company has to run its own. This is a forecast of need, not a confirmed event.<\/p>\n\n\n\n

              Key Takeaways<\/strong><\/h2>\n\n\n\n
                \n
              • 32% of U.S. adults used AI chatbots for health information in the past year, and 41% of those users did so to look up information before deciding whether to see a provider. [1]<\/li>\n\n\n\n
              • OpenAI reports 1.5 million to nearly 2 million U.S. health-insurance messages a week on ChatGPT, about 78 million to 104 million a year at a constant rate (calculated). [2]<\/li>\n\n\n\n
              • The best-known drug-information chatbot study found 26% of evaluated answers did not match reference data, but it tested one product in 2024. [3][4]<\/li>\n\n\n\n
              • A randomized Oxford trial found LLM users did not decide better than a control group. [5]<\/li>\n\n\n\n
              • No public study tests AI accuracy on manufacturer program terms, which are the main content of a PSP.<\/li>\n\n\n\n
              • IQVIA reported that abandonment rises with out-of-pocket cost, most sharply above $125 for commercial patients. [6]<\/li>\n\n\n\n
              • PSP safety reports are solicited reports in the EU and fall under “any source” review in the U.S. A private chatbot chat is outside the company’s receipt. [8][9]<\/li>\n\n\n\n
              • Teams can measure the gap with a documented protocol: fixed questions, logged platform and date, current reference documents, and a five-category error scheme.<\/li>\n<\/ul>\n\n\n\n

                FAQ<\/strong><\/h2>\n\n\n\n

                Do patients really ask AI about drug costs before filling a prescription?<\/strong><\/h3>\n\n\n\n

                Yes for health insurance, with a caveat for drugs. OpenAI reports 1.5 million to nearly 2 million health-insurance messages a week in the U.S., including questions on prices and cost-sharing. [2] It does not report counts for drug-specific cost questions.<\/p>\n\n\n\n

                Is an AI answer about a copay program reliable?<\/strong><\/h3>\n\n\n\n

                No published study measures this. Studies of clinical drug content found 26% of evaluated answers did not match reference data in one 2024 test. [4] Program terms change, so check the manufacturer’s current terms.<\/p>\n\n\n\n

                Can Medicare patients use manufacturer copay cards?<\/strong><\/h3>\n\n\n\n

                Manufacturers generally exclude them. OIG warned in 2014 that coupons used for federally paid drugs create Anti-Kickback Statute risk for the manufacturer. [7]<\/p>\n\n\n\n

                What is the 2026 Medicare Part D out-of-pocket cap?<\/strong><\/h3>\n\n\n\n

                It is $2,100, up from $2,000 in 2025. [12]<\/p>\n\n\n\n

                Does a patient’s AI chat trigger adverse event reporting?<\/strong><\/h3>\n\n\n\n

                The rules cited here attach to information the applicant obtains or receives. [9] A private chat the company never receives is outside that text. Confirm with PV and Legal for your case.<\/p>\n\n\n\n

                How are patient support program safety reports classified in the EU?<\/strong><\/h3>\n\n\n\n

                GVP Module VI, section VI.C.2.2.11, treats them as solicited reports, and the marketing authorisation holder must assess causality. [8] Serious suspected reactions are reported within 15 days and non-serious EU reactions within 90 days under Directive 2001\/83\/EC, Article 107(3). [8]<\/p>\n\n\n\n

                How does cost affect whether patients start therapy?<\/strong><\/h3>\n\n\n\n

                IQVIA found that commercial new-to-brand abandonment rose 27% from 2016 to 2020, mainly among patients asked to pay more than $50 and especially more than $125. [6] The analysis is several years old.<\/p>\n\n\n\n

                Why did the Oxford trial matter for drug information?<\/strong><\/h3>\n\n\n\n

                It found that LLM access did not improve people’s health decisions in a randomized setting, partly because users did not know what to tell the model and answers mixed good and bad advice. [5]<\/p>\n\n\n\n

                How many AI answers should a monitoring test include?<\/strong><\/h3>\n\n\n\n

                The number depends on the question. A design of 20 questions on 5 platforms for 4 weekly runs gives 400 responses. State the sample size and do not generalize beyond it.<\/p>\n\n\n\n

                What did TrumpRx change for cash-paying patients?<\/strong><\/h3>\n\n\n\n

                It launched on February 5, 2026, with more than 40 drugs from five manufacturers. Launch coverage listed Wegovy injectable at an average $350 against a $1,349 list price. [11] Prices may have changed since launch.<\/p>\n\n\n\n

                References<\/strong><\/h2>\n\n\n\n
                  \n
                1. KFF. (2026, March 25). Poll: 1 in 3 adults are turning to AI chatbots for health information, equaling the share who use social media for health<\/em>. https:\/\/www.kff.org\/health-information-trust\/poll-1-in-3-adults-are-turning-to-ai-chatbots-for-health-information-equaling-the-share-who-use-social-media-for-health\/<\/li>\n\n\n\n
                2. OpenAI. (2026, January). AI as a healthcare ally<\/em>. https:\/\/cdn.openai.com\/pdf\/2cb29276-68cd-4ec6-a5f4-c01c5e7a36e9\/OpenAI-AI-as-a-Healthcare-Ally-Jan-2026.pdf<\/li>\n\n\n\n
                3. Andrikyan, W., Sametinger, S. M., Kosfeld, F., Jung-Poppe, L., Fromm, M. F., Maas, R., & Nicolaus, H. F. (2024). Artificial intelligence-powered chatbots in search engines: A cross-sectional study on the quality and risks of drug information for patients. BMJ Quality & Safety<\/em>, 34(2), 100. https:\/\/qualitysafety.bmj.com\/content\/34\/2\/100.info<\/li>\n\n\n\n
                4. News-Medical. (2024, October 10). Researchers warn against relying on AI chatbots for drug safety information<\/em>. https:\/\/www.news-medical.net\/news\/20241010\/Researchers-warn-against-relying-on-AI-chatbots-for-drug-safety-information.aspx<\/li>\n\n\n\n
                5. University of Oxford, Nuffield Department of Primary Care Health Sciences. (2026). New study warns of risks in AI chatbots giving medical advice<\/em> (reporting Nature Medicine, “Clinical knowledge in LLMs does not translate to human interactions”). https:\/\/www.phc.ox.ac.uk\/news\/new-study-warns-of-risks-in-ai-chatbots-giving-medical-advice<\/li>\n\n\n\n
                6. IQVIA. (2021, November 30). Understanding the impact of cost sharing in pharma<\/em>. https:\/\/www.iqvia.com\/locations\/united-states\/blogs\/2021\/11\/understanding-the-impact-of-cost-sharing-in-pharma<\/li>\n\n\n\n
                7. Ropes & Gray LLP. (2014, September). OIG issues special advisory bulletin on pharmaceutical manufacturer copayment coupons<\/em> (summarizing HHS OIG Special Advisory Bulletin of September 19, 2014). https:\/\/www.ropesgray.com\/en\/insights\/alerts\/2014\/09\/oig-issues-special-advisory-bulletin-on-pharmaceutical-manufacturer-copayment-coupons<\/li>\n\n\n\n
                8. Touraille, G. (n.d.). Management of safety data from patient support programmes and market research programmes: Overview of legal requirements applicable to marketing authorisation holders<\/em> [Conference presentation]. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-management-safety-data-patient-support-programmes-and-market-research-programmes-overview-legal-requirements-applicable-marketing-authorisation-holders-gilles-touraille_en.pdf<\/li>\n\n\n\n
                9. Postmarketing reports of adverse drug experiences, 21 C.F.R. \u00a7 314.80 (2012). U.S. Government Publishing Office. https:\/\/www.govinfo.gov\/content\/pkg\/CFR-2012-title21-vol5\/pdf\/CFR-2012-title21-vol5-sec314-80.pdf<\/li>\n\n\n\n
                10. Guidehouse. (2025). 2025 patient services trends survey report<\/em>. https:\/\/guidehouse.com\/-\/media\/new-library\/industries\/health\/documents\/2025\/2025-hc-pub-002-c-patient-services-trends-survey-report.pdf<\/li>\n\n\n\n
                11. Pharmaceutical Technology. (2026, February 6). TrumpRx launches to slash drug prices for cash-paying US patients<\/em>. https:\/\/www.pharmaceutical-technology.com\/news\/trumprx-launches-to-slash-drug-prices-for-cash-paying-us-patients\/<\/li>\n\n\n\n
                12. Optum. (n.d.). 3 key changes in 2026 for patients with Medicare Part D<\/em>. https:\/\/business.optum.com\/en\/support\/hcp-resources\/medicare-part-d-changes-2026.html<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                  In a KFF poll fielded February 24 to March 2, 2026, 32% of U.S. adults said they had used an […]<\/p>\n","protected":false},"author":1,"featured_media":1281,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=1280"}],"version-history":[{"count":1,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1280\/revisions"}],"predecessor-version":[{"id":1282,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1280\/revisions\/1282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/1281"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=1280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=1280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=1280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}